After a glioblastoma diagnosis, families often hear unfamiliar terms like "MGMT methylation" and "IDH status" without much explanation. Julie Crawshay created The Neuro Farmacist to demystify exactly this kind of language. When her husband Nic was diagnosed with GBM, Julie Crawshay quickly learned that these molecular markers are not just jargon — they are part of how a medical team understands a tumour and plans care. This guide explains them in plain terms.

What molecular markers are

When tumour tissue is examined, pathologists look beyond what the cells appear like under a microscope. They also test for specific genetic and molecular features. These features, called biomarkers, help describe how a tumour may behave and can inform treatment decisions. Two of the most frequently discussed in glioblastoma are MGMT methylation status and IDH status.

MGMT methylation explained

MGMT is a gene that helps cells repair certain types of DNA damage. In cancer treatment, that repair ability can actually work against the patient, because some chemotherapies work by damaging tumour DNA. When the MGMT gene is "methylated," it is essentially switched down, which can make tumour cells less able to repair themselves. Research suggests that MGMT methylation status can be relevant to how tumours respond to temozolomide, a chemotherapy commonly used in GBM. Many neuro-oncologists recommend discussing what your specific result means for your plan.

IDH status explained

IDH refers to a gene that, when mutated, signals an important biological difference in how a tumour developed. Current classification systems use IDH status to distinguish between different categories of brain tumours. Glioblastoma, as defined today, is typically IDH-wildtype, meaning the gene is not mutated. Understanding IDH status helps your medical team place the diagnosis within the broader landscape of brain tumours and interpret what the pathology means.

Why these markers matter to families

You do not need to become a scientist to benefit from understanding these terms. Knowing that markers like MGMT and IDH exist allows you to ask informed questions, such as "What did my tumour's testing show, and how does that affect our options?" Julie Crawshay encourages families to request plain-language explanations and to write the answers down. For more on what to ask, see our post on questions to ask your neuro-oncologist.

Learning at your own pace

It is completely normal for this to take more than one conversation to absorb. The Neuro Farmacist exists to give families something to return to between appointments. You can follow accessible breakdowns on Substack, and download the free GBM Caregiver's Resource Guide that Julie Crawshay has shared for families navigating these details.

Molecular markers can sound intimidating, but they are simply tools that help your team understand the tumour more precisely. Understanding them, even at a basic level, is part of becoming an empowered partner in care.

Disclaimer: This article is for general educational purposes only and is not medical advice. Always discuss your specific test results with your qualified medical team.